Equipping CAR-modified T cells with a brake to prevent chronic Adverse effects

Current Gene Therapy

Volumn 12, Issue 6, 2012, Pages 493-495

  Wang, Wei ^a   Wang, Yongsheng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

CD19; Chimeric antigen receptor; Safety; T lymphocytes; Tumor

Indexed keywords

CASPASE 9; CD137 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD28 ANTIGEN; FAS ANTIGEN; GANCICLOVIR; MYC PROTEIN; RITUXIMAB; SITIMAGENE CERADENOVEC;

APLASIA; APOPTOSIS; ARTICLE; CHIMERIC ANTIGEN RECEPTOR MODIFIED T LYMPHOCYTE; CYTOTOXICITY; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX VIRUS; HUMAN; LEUKEMIA; SUICIDE GENE; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD19; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; GENETIC ENGINEERING; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA; RISK FACTORS; T-LYMPHOCYTES;

EID: 84870178913     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652312803519751     Document Type: Article

References (28)

1. Vera JF, Brenner MK, Dotti G. Immunotherapy of human cancers using gene modified T lymphocytes. Curr Gene Ther 2009; 9: 396-408.
2. Bridgeman JS, Hawkins RE, Hombach AA, et al. Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther 2010; 10: 77-90.
3. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of Blineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010; 116: 4099-102.
4. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-29.
5. Markley JC, Sadelain M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 2010; 115: 3508-19.
6. Haynes NM, Trapani JA, Teng MWL, et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 2002; 100: 3155-63.
7. Kalos M, Levine BL, Porter DL, et al. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. Science Translational Medicine 2011; 3: 95ra73-95ra73.
8. Milone MC, Fish JD, Carpenito C, et al. Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo. Mol Ther 2009; 17: 1453-64.
9. Hombach AA, Abken H. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. Int J Cancer 2011; 129: 2935-44.
10. Pule MA, Straathof KC, Dotti G, et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005; 12: 933-41.
11. Wang J, Jensen M, Lin Y, et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 2007; 18: 712-25.
12. Chinnasamy D, Yu Z, Theoret MR, et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest 2010; 120: 3953-68.
13. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26: 5233-39.
14. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005; 202: 907-12.
15. Kaneko S, Mastaglio S, Bondanza A, et al. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 2009; 113: 1006-15.
16. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-33.
17. Morgan RA, Yang JC, Kitano M, et al. Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2. Mol Ther 2010; 18: 843-51.
18. Brentjens R, Yeh R, Bernal Y, et al. Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial. Mol Ther 2010; 18: 666-68.
19. Chmielewski M, Hombach A, Heuser C, et al. T Cell Activation by Antibody-Like Immunoreceptors: Increase in Affinity of the Single-Chain Fragment Domain above Threshold Does Not Increase T Cell Activation against Antigen-Positive Target Cells but Decreases Selectivity. J Immunol 2004; 173: 7647-53.
20. Zhao Y, Moon E, Carpenito C, et al. Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor. Cancer Res 2010; 70: 9053-61.
21. Till BG, Jensen MC, Wang JJ, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008; 112: 2261-71.
22. Bonini C. HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia. Science 1997; 276: 1719-24.
23. Uckert W, Kammertons T, Haack K, et al. Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum Gene Ther 1998; 9: 855-65.
24. Traversari C, Marktel S, Magnani Z, et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 2007; 109: 4708-15.
25. Garin MI. Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 2001; 97: 122-29.
26. Casucci M, Bondanza A. Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes. J Cancer 2011; 2: 378-82.
27. Kieback E, Charo J, Sommermeyer D, et al. A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer. Proceedings of the National Academy of Sciences of the United States of America 2008; 105: 623-28.
28. Griffioen M, van Egmond EHM, Kester MGD, et al. Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy. Haematologica 2009; 94: 1316-20